https://orcid.org/0000-0003-4666-7495
Overview
1. Investigator-initiated and multi-center clinical trials testing new treatments for amyotrophic lateral sclerosis and diabetic neuropathy.
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
Current Duke Appointments & Affiliations
Stewart, Hughes and Wendt Distinguished Professor
·
2023 - Present
Neurology, Neuromuscular Disease,
Neurology
Professor of Neurology
·
2018 - Present
Neurology, Neuromuscular Disease,
Neurology
Faculty Network Member of the Duke Institute for Brain Sciences
·
2011 - Present
Duke Institute for Brain Sciences,
University Institutes and Centers
Associate of the Duke Initiative for Science & Society
·
2017 - Present
Duke Science & Society,
University Initiatives & Academic Support Units
Recent Scholarly Works
ALSUntangled #82: N-acetylcysteine.
Journal article Amyotroph Lateral Scler Frontotemporal Degener · August 2026 N-acetylcysteine is a thiol-containing compound and a precursor of glutathione, with mechanistic plausibility for ALS, including reducing oxidative stress, regulating neuroinflammation, and mitigating mitochondrial dysfunction. Preclinical studies have yie ... Full text Link to item CiteExamining IGFBP7 as a potential therapeutic target in people with ALS.
Journal article Amyotroph Lateral Scler Frontotemporal Degener · May 2026 A single nucleotide variant in an insulin-like growth factor (IGFBP7) promotor, which reduces IGFBP7 levels in brain, was previously associated with an ALS "reversal" phenotype. This raises the question of whether IGFBP7 might be a therapeutic target in AL ... Full text Link to item CiteALSUntangled #81: Pyridostigmine (mestinon®).
Journal article Amyotroph Lateral Scler Frontotemporal Degener · May 2026 Pyridostigmine (Mestinon®, Bausch Health, Canada Inc.) increases acetylcholine availability at the neuromuscular junction, enhancing transmission. Preclinical studies suggest that neuromuscular junction dysfunction develops early in ALS, and pyridostigmine ... Full text Link to item CiteRecent Grants
Healy ALS Platform Study - Regimen I - NUZ-001 TO#14
Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2026 - 2030SEA-NOBI-ALS
Clinical TrialPrincipal Investigator · Awarded by WideTrial, Inc. · 2025 - 2028Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATE)
ResearchPrincipal Investigator · Awarded by University of Miami · 2025 - 2027View All Grants
Education
University of Connecticut ·
1995
Ph.D.
University of Connecticut ·
1995
M.D.